Avenue Therapeutics, Inc. (ATXI): R&D Expense
$1.04M
Year ended 2025-12-31
$881.0K
Trailing 12 months to 2026-06-30
-27.3%
3-year compound annual growth
-18.4%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.04M | -84.4% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $6.64M | +8.4% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $6.13M | +127.2% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $2.70M | +115.2% | 2024-03-18, From 2022-01-01 |
| 2021-12-31 | $1.25M | -56.2% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $2.87M | -87.1% | 2022-03-25, From 2020-01-01 |
| 2019-12-31 | $22.19M | +25.4% | 2021-03-31, From 2019-01-01 |
| 2018-12-31 | $17.70M | +164.2% | 2020-03-30, From 2018-01-01 |
| 2017-12-31 | $6.70M | +403.2% | 2019-03-12, From 2017-01-01 |
| 2016-12-31 | $1.33M | n/a | 2018-03-01, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Northwest Biotherapeutics Inc (NWBO) | 2025-12-31 | $28.79M | -17.5% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $3.78M | -39.1% |
| IGC Pharma, Inc. (IGC) | 2025-03-31 | $3.65M | -3.1% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $20.20M | -24.3% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
Compare ATXI, NWBO, NRXP, IGC side by side · Screen every company in Pharmaceutical Preparations ↗